G Sanacora

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Nat Rev Drug Discov 7:426-37. 2008
  2. ncbi request reprint Antidepressant effect of ketamine during ECT
    Robert Ostroff
    Am J Psychiatry 162:1385-6. 2005
  3. ncbi request reprint Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 59:284-6. 2006
  4. ncbi request reprint N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
    Daniel L Lafleur
    Psychopharmacology (Berl) 184:254-6. 2006
  5. ncbi request reprint Beyond monoamines: glutamatergic function in mood disorders
    Akira Kugaya
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    CNS Spectr 10:808-19. 2005
  6. pmc From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 73:1172-9. 2013
  7. ncbi request reprint Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy
    G Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
    Arch Gen Psychiatry 56:1043-7. 1999
  8. ncbi request reprint Clinical studies implementing glutamate neurotransmission in mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University, School of Medicine, New Haven, Connecticut 06519, USA
    Ann N Y Acad Sci 1003:292-308. 2003
  9. ncbi request reprint Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    Arch Gen Psychiatry 61:705-13. 2004
  10. ncbi request reprint Increased cortical GABA concentrations in depressed patients receiving ECT
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Psychiatry 160:577-9. 2003

Detail Information

Publications42

  1. pmc Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Nat Rev Drug Discov 7:426-37. 2008
    ..We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders...
  2. ncbi request reprint Antidepressant effect of ketamine during ECT
    Robert Ostroff
    Am J Psychiatry 162:1385-6. 2005
  3. ncbi request reprint Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 59:284-6. 2006
    ..The purpose of this study was to determine whether treatment of major depression with cognitive behavioral therapy (CBT) produces similar changes in cortical GABA concentrations...
  4. ncbi request reprint N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
    Daniel L Lafleur
    Psychopharmacology (Berl) 184:254-6. 2006
    ..N-acetylcysteine (NAC) is a readily available amino acid compound that is thought to attenuate glutamatergic neurotransmission. NAC may be useful in treating psychiatric disorders involving glutamatergic dysfunction such as OCD...
  5. ncbi request reprint Beyond monoamines: glutamatergic function in mood disorders
    Akira Kugaya
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    CNS Spectr 10:808-19. 2005
    ....
  6. pmc From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 73:1172-9. 2013
    ..Lastly, we discuss the effect of antidepressants on glial cell function and the possibility of targeting glial cells in the quest to develop novel therapeutics...
  7. ncbi request reprint Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy
    G Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
    Arch Gen Psychiatry 56:1043-7. 1999
    ..In this study we used in vivo proton magnetic resonance spectroscopy to investigate the hypothesis that abnormalities in the GABA neurotransmitter system are associated with the neurobiologic processes of depression...
  8. ncbi request reprint Clinical studies implementing glutamate neurotransmission in mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University, School of Medicine, New Haven, Connecticut 06519, USA
    Ann N Y Acad Sci 1003:292-308. 2003
    ..Here we review the available literature in the field and suggest a possible pathophysiological model that may account for the many of the findings...
  9. ncbi request reprint Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    Arch Gen Psychiatry 61:705-13. 2004
    ..An initial report, using this technique, suggested that occipital cortex GABA concentrations are reduced in patients with major depressive disorder (MDD) relative to healthy comparison subjects...
  10. ncbi request reprint Increased cortical GABA concentrations in depressed patients receiving ECT
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Psychiatry 160:577-9. 2003
    ..The purpose of this study was to determine if cortical GABA concentrations increase following a course of ECT...
  11. ncbi request reprint Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Neuropsychopharmacology 29:1166-71. 2004
    ..The addition of the alpha2-antagonist yohimbine to fluoxetine appears to hasten the antidepressant response. There is also a trend suggesting an increased percentage of responders to the combined treatment at the end of the 6-week trial...
  12. ncbi request reprint Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Psychiatry 159:663-5. 2002
    ..The goal of this study was to determine whether these occipital cortex GABA concentrations are altered after administration of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression...
  13. pmc Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms
    Gerard Sanacora
    Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 61:822-5. 2007
    ..Recent evidence suggests that riluzole and other agents that target glutamate neurotransmission may show antidepressant activity...
  14. ncbi request reprint GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action
    Gerard Sanacora
    Yale University School of Medicine, Department of Psychiatry, USA
    CNS Neurol Disord Drug Targets 6:127-40. 2007
    ..This review outlines the existing literature investigating the possible involvement of GABA in the neurobiology of depression and briefly highlights how this information may afford new targets for antidepressant drug development...
  15. ncbi request reprint New understanding of mechanisms of action of bipolar medications
    Gerard Sanacora
    Yale Depression Research Program, Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
    J Clin Psychiatry 69:22-7. 2008
    ....
  16. pmc Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
    M Banasr
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06437, USA
    Mol Psychiatry 15:501-11. 2010
    ....
  17. ncbi request reprint Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
    J H Krystal
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Mol Psychiatry 7:S71-80. 2002
    ..Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders...
  18. ncbi request reprint Joint analysis of repeatedly observed continuous and ordinal measures of disease severity
    R V Gueorguieva
    Division of Biostatistics, Department of Epidemiology and Public Health, School of Medicine, Yale University, 60 College St, New Haven, CT 06520, USA
    Stat Med 25:1307-22. 2006
    ..Data from a depression clinical trial are used for illustration...
  19. pmc Targeting glial physiology and glutamate cycling in the treatment of depression
    Gerald W Valentine
    Yale University, Department of Psychiatry, CNRU, 34 Park Street, New Haven, CT 06508, USA
    Biochem Pharmacol 78:431-9. 2009
    ..Because riluzole has antidepressant effects in both animal models and human subjects, it may represent the prototype for a novel class of antidepressants with the modulation of glial physiology as a primary mechanism of action...
  20. ncbi request reprint Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders
    J H Krystal
    Department of Psychiatry, Yale University School of Medicine, Connecticut, USA
    Med Clin North Am 85:559-77. 2001
    ..The current era is an exciting one for psychiatric research and the rapidity with which advances are being made is a source of hope to patients with these disorders and for society...
  21. ncbi request reprint Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial
    Edward B Perry
    Department of Psychiatry, VA Connecticut Healthcare System, Psychiatry Service 116A, 950 Campbell Avenue, West Haven, CT 06516, USA
    J Clin Psychiatry 65:238-43. 2004
    ..Here, we report on a double-blind, randomized, controlled 6-week study of pindolol augmentation of selective serotonin reuptake inhibitors (SSRIs) in depressed outpatients resistant to SSRI monotherapy...
  22. doi request reprint It is time to take a stand for medical research and against terrorism targeting medical scientists
    John H Krystal
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 63:725-7. 2008
  23. pmc Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus
    Golam M I Chowdhury
    Department of Diagnostic Radiology, Magnetic Resonance Research Center, Yale University School of Medicine, New Haven, Connecticut, USA
    J Cereb Blood Flow Metab 28:1892-7. 2008
    ..2). Our findings indicate that contrary to expectation chronic riluzole enhanced glucose oxidative metabolism and glutamate/glutamine cycling...
  24. ncbi request reprint Riluzole in the treatment of mood and anxiety disorders
    Christopher Pittenger
    Clinical Neuroscience Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA
    CNS Drugs 22:761-86. 2008
    ..Riluzole may hold promise for the treatment of several psychiatric conditions, possibly through its ability to modulate pathologically dysregulated glutamate levels, and merits further investigation...
  25. doi request reprint Major depression: emerging therapeutics
    Srijan Sen
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Mt Sinai J Med 75:204-25. 2008
    ..In this review, we discuss the biological basis and preclinical and clinical evidence for a series of promising classes of antidepressants developed primarily out of a pathophysiologically informed approach...
  26. ncbi request reprint Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy
    C Neill Epperson
    Department of Psychiatry, Yale University School of Medicine, University Towers Suite 2H, 100 York Street, New Haven, CT 06511, USA
    Biol Psychiatry 57:44-8. 2005
    ..Given that nicotine modulates amino acid neurotransmission, we sought to examine the impact of nicotine on cortical gamma-aminobutyric acid (GABA) levels in male and female smokers...
  27. pmc Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
    John H Krystal
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, United States
    Drug Discov Today 14:690-7. 2009
    ..In considering neuroplasticity as a target for the treatment of psychiatric disorders, we build on exciting new findings in the areas of anxiety disorders, mood disorders, and schizophrenia...
  28. ncbi request reprint Monoamine depletion in unmedicated depressed subjects
    Robert M Berman
    Abraham Ribicoff Center Clinical Neuroscience Research Unit of the Connecticut Mental Health Center, New Haven, Connecticut, USA
    Biol Psychiatry 51:469-73. 2002
    ..This study assesses the integrated role of these monoamine systems in depressed patients...
  29. ncbi request reprint Antidepressant-like effects of ceftriaxone in male C57BL/6J mice
    Yann S Mineur
    Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut 06519, USA
    Biol Psychiatry 61:250-2. 2007
    ..Recent evidence that beta-lactam antibiotic agents stimulate uptake of glutamate suggests that this class of compounds might possess antidepressant-like activity...
  30. ncbi request reprint Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression
    Jaakko Lappalainen
    Yale University School of Medicine, Department of Psychiatry, VA Connecticut Healthcare System, New Haven, Connecticut 06516, USA
    Am J Med Genet B Neuropsychiatr Genet 124:81-6. 2004
    ..Furthermore, these results suggest that common genetic variation within the GAD67 gene does not play a major role in the predisposition to unipolar depression...
  31. ncbi request reprint Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors
    Akira Kugaya
    Department of Psychiatry, Yale University, New Haven, Connecticut, USA
    Biol Psychiatry 56:497-502. 2004
    ..This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations...
  32. ncbi request reprint Sex differences in diencephalon serotonin transporter availability in major depression
    Julie K Staley
    Department of Psychiatry, Yale University School of Medicine and West Haven VA Connecticut Health Care System, CT 06516, USA
    Biol Psychiatry 59:40-7. 2006
    ..The present study evaluated if previous findings that demonstrated decreased 5-hydroxytryptamine (5-HT) transporter availability in depressed patients would be confirmed in a larger sample and also evaluated sex differences...
  33. ncbi request reprint Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial
    Vladimir Coric
    Department of Psychiatry, Yale University School of Medicine and Connecticut Mental Health Center, 34 Park Street, New Haven, CT 06519, USA
    Biol Psychiatry 58:424-8. 2005
    ..Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD...
  34. ncbi request reprint ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment
    A C Chen
    Abraham Ribicoff Research Facilities, Yale University School of Medicine, Connecticut Mental Health Center, New Haven 06508, USA
    J ECT 17:27-32. 2001
    ..These findings are of increasing interest, as they relate to the use of ECT in the treatment of depression, and the specific anesthetic agents that are used...
  35. ncbi request reprint The NMDA receptor as a therapeutic target in major depressive disorder
    Christopher Pittenger
    Department of Psychiatry, Yale University, USA
    CNS Neurol Disord Drug Targets 6:101-15. 2007
    ..Nevertheless, other effects of such medications, including both cognitive side effects and their psychotomimetic properties, complicate such an application and represent a challenge to the development of clinically useful agents...
  36. ncbi request reprint Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT
    Akira Kugaya
    Department of Psychiatry, Yale University, New Haven, CT, USA
    Biol Psychiatry 54:792-9. 2003
    ..No in vivo study has been reported to measure postsynaptic GABA receptors in the patients...
  37. ncbi request reprint Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study
    Lisa Fenton
    Yale Depression Research Program, Yale University School of Medicine, New Haven, CT 06511, USA
    J ECT 22:196-8. 2006
    ..The goal of this study was to explore the potential of providing cognitive behavioral therapy (CBT) after an index course of electroconvulsive therapy (ECT) for depression to improve long-term outcome...
  38. pmc Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications
    Srijan Sen
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, Connecticut 06519, USA
    Biol Psychiatry 64:527-32. 2008
    ..Converging lines of evidence implicate the neurotrophin brain-derived neurotrophic factor (BDNF) in the pathophysiology of major depression. Recent studies have begun to explore the relationship between serum BDNF and depression...
  39. ncbi request reprint Reviewing medications for bipolar disorder: understanding the mechanisms of action
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
    J Clin Psychiatry 70:e02. 2009
    ..Using the neuroplasticity model of mood disorders, specific neurobiological mechanisms can be targeted for treatment...
  40. ncbi request reprint Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression
    Joseph F Cubells
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
    Biol Psychiatry 51:358-64. 2002
    ..Plasma DbetaH is under genetic control by the structural locus encoding DbetaH protein, DBH. This study tested the hypothesis that diagnosis-specific allelic variation at DBH accounts for lower plasma DbetaH in UDPF...
  41. ncbi request reprint Riluzole augmentation for treatment-resistant depression
    Gerard Sanacora
    Am J Psychiatry 161:2132. 2004
  42. ncbi request reprint Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression
    Thomas D Geracioti
    Research Service, VA Medical Center, 3200 Vine St, Box 151, Cincinnati, OH 45220, USA
    Am J Psychiatry 163:637-43. 2006
    ..The authors also sought to determine if CNS substance P concentrations change on provocation of symptoms in PTSD patients...

Research Grants12

  1. MRS STUDIES OF CORTICAL GABA IN DEPRESSION
    Gerard Sanacora; Fiscal Year: 2003
    ..This novel line investigation will open previously inaccessible areas of research, with a broad range of future applications. ..
  2. 1/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Gerard Sanacora; Fiscal Year: 2010
    ....
  3. 13C Measurement of GABA Synthesis in Depression
    Gerard Sanacora; Fiscal Year: 2009
    ..In addition, we will continue to investigate the potential association between cortical GABA concentrations and both the various clinical subtypes of depression and allelic variants of the GAD65 gene. ..
  4. Studies of Amino Acid Neurotransmitter Contributions to Depression
    Gerard Sanacora; Fiscal Year: 2007
    ..This work has direct clinical relevance since it is likely to lead to the development of novel diagnostic methods and treatment modalities for these disorders. ..
  5. Effects of Stress and Glutamatergic Agents on Glutamate Cycling and Behavior
    Gerard Sanacora; Fiscal Year: 2010
    ....